Biopharmaceutical Contract Manufacturing Market: Oncology Segment by Therapeutic Area to Dominate the Global Market Through 2027: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027

  • Published: 2017-09-06
  • Report Code: REP-GB-2982
  1. Home
  2. Syndicated Research

  3. Biopharmaceutical Contract Manufacturing Market Analysis

An Incisive, In-depth Analysis on the Biopharmaceutical Contract Manufacturing Market

This study offers a comprehensive, 360 degree analysis on the Biopharmaceutical Contract Manufacturing market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Biopharmaceutical Contract Manufacturing market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Request a sample
Ask An Analyst
Request Special Price
Request Methodology

Key Insights

Strong Biologics Pipeline Fuels the Demand for biopharmaceutical contract manufacturing companies

The current biologics-development pipeline supports an outlook of continued healthy growth for biopharmaceutical contract manufacturing companies. The number of biotech patents applied for every year has been growing at approximately 23 percent annually. There are currently more than 1,500 biomolecules undergoing clinical trials and the success rate for biologics has so far been over twice of that of small-molecule products. FDA-approved recombinant therapeutics has increased by approximately 400% between 2003 and 2017, with 31 approvals of recombinant biopharmaceuticals in 2017. Biopharmaceutical contract manufacturing plays an important role in commercial manufacturing as well as the late clinical phase of biologics production. Big pharma companies have limited capacity for biologic production, fuelling outsourcing of biologic production to biopharmaceutical contract manufacturing companies.

Evident Move towards Fewer Platforms from Large Number of Platforms per Company in Biopharmaceutical Contract Manufacturing

Biopharmaceutical contract manufacturing companies are becoming specialized in terms of the use of platforms. Mammalian is the platform of choice across most biopharmaceutical contract manufacturing entities. The scene for biopharmaceutical contract manufacturing companies has changed quite rapidly since 2003. Less than a fifth of biopharmaceutical contract manufacturing prefer a microbial platform. Presently, pre-commercial bioprocessing is dominated by the use of single-use systems among biopharmaceutical contract manufacturing companies. Commercial sales are also dominated by single-use adoption across biopharmaceutical contract manufacturing facilities. The advantage of using mammalian culture platforms include presence of metabolic and protein processing pathways similar to those in human cells. Chinese hamster ovary (CHO) cell lines have become the dominant expression systems among biopharmaceutical contract manufacturing entities. The biopharmaceutical contract manufacturing industry is gravitating towards using novel platforms with improved performance and new functionalities over conventional protein molecules. Even higher cell culture yields and improved technology have made mammalian manufacturing more cost-effective and easier for biopharmaceutical contract manufacturing companies.

Biopharmaceutical Contract Manufacturing, Though Dominated by Developed Markets, is Gradually Entering Developing Regions

Biopharmaceutical contract manufacturing requires facilities that are highly sterile and free from impurities. Only developed markets were penetrated by biopharmaceutical contract manufacturing entities. North America holds the greatest percentage capacity, followed by Europe and Asia in presence of biopharmaceutical contract manufacturing companies. Reactor capacity in biopharmaceutical contract manufacturing companies is expected to shift slightly from North America to Asia over the forecast period. This is primarily due to rapid expansion in China, Singapore, and Korea, due to government incentives and tax advantages. Biopharmaceutical drugmakers and biopharmaceutical contract manufacturing companies with global supply chains can leverage Asian locations as well. As noted by Merck, there has been rapidly growing demand for biopharmaceutical contract manufacturing in China, with a strong focus on technology improvement. Merck announced establishment of its first Mobius Single-use biopharmaceutical contract manufacturing facility in China in September 2018. The biopharmaceutical contract manufacturing facility will be located in Wuxi, and is expected to be operational by Q1 2019.  

Capacity Utilization is Much Higher for Biopharmaceutical Contract Manufacturing, and is Growing over the Years

It is worth noting that, biopharmaceutical contract manufacturing capacity utilization rates have been increasing steadily over the years. Existing capacity utilization is a key factor that differentiates customer base and demand in biopharmaceutical contract manufacturing market. More specifically, the trend seems to have been bent towards contracting out the late-stage, scale-up, and commercial manufacturing activities in biopharmaceutical contract manufacturing. Capacity utilization is said to be much better for biopharmaceutical contract manufacturing players than small molecule contract manufacturing players. Across the biopharmaceutical contract manufacturing market, rates are said to vary between 65-75%. Less than 30% biopharmaceutical contract manufacturing respondents in large surveys have noted that, their organizations have not planned any capacity expansion in the next five years. Rather, a large portion of biopharmaceutical contract manufacturing respondents note increasing existing capacity utilization in order to be sustainably profitable. Biopharmaceutical contract manufacturing players note that, 'facility constraints' are the primary bottleneck factor, followed by the inability to hire proper trained staff in places where capacity expansion has moved down the priority list.

Biopharmaceutical Contract Manufacturing Industry Witnessing Consolidation

The biopharmaceutical contract manufacturing market is witnessing a wave of consolidation. Consolidating is expected to help biopharmaceutical contract manufacturing companies in gaining access to advanced technologies, expanding breadth of capabilities and entering new geographic markets inorganically. Pressure is surmounting on accelerating the process of drug development as well as commercialization processes for biopharmaceutical contract manufacturing companies. Every year, an increasing number of drug candidates are receiving accelerated approval designations such as FastTrack, Priority Review, etc. , fuelling the demand for more efficient, full-service biopharmaceutical contract manufacturing providers, with better capacity utilization rates, strong process support to cater within a short period of time for clinical and commercial production.

Changing Regulatory Dynamics are Hampering the Growth of the Biopharmaceutical Contract Manufacturing Market

Global regulatory policies, cGMP, and inspection regimes tightening supply chain security issues across emerging countries have large impact on the cost of the final products. New entrants willing to enter into biopharmaceuticals contract manufacturing market are facing financial challenges. This makes market entry a costly decision for SMEs. Such changing regulatory dynamics are hampering the growth of the biologics contract manufacturing market in some regions.

Note: For detailed analysis on all the key market factors, request a sample.

Competitive Landscape

The FMI report titled “Biopharmaceutical Contract Manufacturing  Market provides detailed information about the growth parameters of the biopharmaceutical contract manufacturing companies. It includes detailed assessment of the competitive environment in the biopharmaceutical contract manufacturing market. The market study provides comprehensive data on each stakeholder in the biopharmaceutical contract manufacturing market, including Lonza Group Ag, Baxter Biopharma solution, Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim Gmbh, Patheon N.V., Rentschler Biotechnologie Gmbh, Biomeva Gmbh, Probiogen Ag., Cytovance Biologics Inc, Kbi Biopharma Inc, Wuxi Biologics (Cayman) Inc., Abzena Plc, Vetter Pharma International Gmbh, Sandoz International Gmbh, Catalent Inc., AbbVie Contract Manufacturing, and Ajinomoto Althea Inc. The report provides readers with all-encompassing data on each biopharmaceutical contract manufacturer’s revenue shares, winning strategies, and latest information on mergers and acquisitions in the biopharmaceutical contract manufacturing market.

Considering the rapidly-growing biopharmaceutical contract manufacturing market, expansion in emerging economies is taking center stage. In this regard, some of the latest M&A big ticket deals in the biopharmaceutical contract manufacturing market are Merck KGaA’s acquisition of Sigma-Aldrich, Pfizer’s complete acquisition of Hospira, Patheon and DSM merger, and merger of Cambridge Major Laboratories with AAIPharma to form Alcami. Geographical expansions include Merck’s expansion of a biologics facility in China (Wuxi), Merck’s operation expansion in Gillingham, U.K., and a strategic alliance between Samsung Biologics and Merck in South Korea, among many others.

Note: For full coverage of the competitive landscape, get in touch with our experts.

Definition

A biopharmaceutical contract manufacturing firm provides comprehensive services from drug development to drug manufacturing. In this report, the biopharmaceuticals contract manufacturing market is further categorized into platform type, product type, application, and therapeutic area. The biopharmaceutical contract manufacturing report analyses the demand from outsourced production.

About the Report

The market study on the biopharmaceutical contract manufacturing market was recently published by FMI, which provides comprehensive information about the most important market dynamics that prove instrumental in the growth of the biopharmaceutical contract manufacturing market during 2016-2026. Companies in the Biopharmaceutical Contract Manufacturing Market can find the most accurate quantitative and qualitative information about the growth parameters of the other biopharmaceutical contract manufacturers, which can help them develop data-driven business strategies in the coming future.

Segmentation

The FMI report on biopharmaceutical contract manufacturing market provides salient information on market players. The biopharmaceutical contract manufacturing market is segmented by geographical region, product type, platform type, therapeutic type, and application, to analyze the segment-wise growth of the biopharmaceutical contract manufacturing market. Based on geographical region, the biopharmaceutical contract manufacturing market is segmented into seven regions – North America, Latin America, Western Europe, Eastern Europe, Japan, Asia Pacific Excluding Japan (APEJ), and the Middle East & Africa (MEA). The biopharmaceutical contract manufacturing market is segmented into product types, viz., monoclonal antibodies, recombinant protein, vaccines, insulin, interferons growth factors, and others. Depending on the platform type, the biopharmaceutical contract manufacturing market is divided into mammalian and microbial. By therapeutic type, the market is segmented into autoimmune diseases, oncology, metabolic diseases, ophthalmology, cardiovascular diseases, infectious diseases, neurology, respiratory disorders, and others. By application, the biopharmaceutical contract manufacturing market is divided into clinical and commercial.

Additional Questions Answered

Readers can find detailed information about the important positive and negative factors affecting biopharmaceutical contract manufacturing market during the forecast period. Additionally, the biopharmaceutical contract manufacturing market report also contains valuable information that can provide biopharmaceutical contract manufacturers with answers to critical questions, such as

  • Which types of platforms and product types account for the maximum demand for biopharmaceutical contract manufacturing market? Why is it so?
  • Why are the sales of biopharmaceutical contract manufacturing services and products highest in North America? What are the factors customers seek in biopharma CMOs?
  • Which regulations in various regional segments are influencing the strategies of players in the biopharmaceutical contract manufacturing market?
  • Why is APEJ currently attracting lots of traction among most of the leading biopharmaceutical contract manufacturers?
  • What are the current technology trends adopted by various biopharmaceutical contract manufacturing companies?
  • What are the outsourcing strategies being applied by drug manufacturers in order to sustain themselves in the competitive biopharmaceutical contract manufacturing market?

Research Methodology

The process of market research followed at FMI commences with extensive secondary research of the biopharmaceutical contract manufacturing market. Analysts obtain industry-validated, historic, and current data about the demand for biopharmaceutical contract manufacturing across the globe. Comprehensive secondary research is followed by extensive and in-depth primary research, where detailed information about the biopharmaceutical contract manufacturing market is obtained in terms of value (US$ Million). Based on thorough secondary and primary research of the growth parameters of the biopharmaceutical contract manufacturing market, analysts come up with the most precise forecast on how the biopharmaceutical contract manufacturing market will grow during the forecast period.

Note: Request methodology.

Biopharmaceutical Contract Manufacturing Market: Detailed Analysis of the Growth Parameters Helps Market Players to Make Accurate Business Decisions

A study published by FMI – 'Biopharmaceutical Contract Manufacturing Market: Global Industry Analysis and Opportunity Assessment, 2017-2027', consists of a comprehensive assessment of the most important market dynamics. Current growth parameters of the biopharmaceutical contract manufacturing market are obtained with maximum precision. The report features unique and salient factors that may have a huge impact on the development of the biopharmaceutical contract manufacturing market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the biopharmaceutical contract manufacturing market during the upcoming years. The report details current and future growth prospects of the biopharmaceutical contract manufacturing market.

Chapter 1 – Executive Summary

The report commences with the executive summary of the biopharmaceutical contract manufacturing market report, which includes the summary of key findings and key statistics of the biopharmaceutical contract manufacturing market. It also includes the market value (US$ Million) estimates of the leading segments of the biopharmaceutical contract manufacturing market.

Chapter 2 – Market Introduction

Readers can find a detailed taxonomy and the definition of the biopharmaceutical contract manufacturing market in this chapter, which will help understand the basic information about the biopharmaceutical contract manufacturing market dynamics included in the report. Market definitions of the biopharmaceutical contract manufacturing market are included in this chapter.

Chapter 3 – Market View Point

This chapter provides readers with information about the most important global biopharmaceutical contract manufacturing market size 2012-2016, and the forecast for the period 2017-2027. It also details the opportunity analysis and regulatory scenario of the biopharmaceutical contract manufacturing market.

Chapter 4 – North America Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

This chapter includes detailed analysis of the growth of the North American biopharmaceutical contract manufacturing market, along with a country-wise assessment, including the U.S. and Canada. Readers can also find drivers, restraints, regional trends, regulations, and market growth based on platform type, product type, therapeutic area type, and application type of the biopharmaceutical contract manufacturing market in the North American region.

Chapter 5 – Latin America Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

Readers can find detailed information about factors such as key regulations, drivers, barriers, and regional trends that are impacting the growth of the Latin American biopharmaceutical contract manufacturing market. This chapter also includes the growth prospects of the biopharmaceutical contract manufacturing market in leading Latin American countries such as Brazil, Mexico, and the Rest of the Latin American region.

Chapter 6 – Western Europe Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

Important growth prospects of the biopharmaceutical contract manufacturing market based on its platform type, product type, therapeutic area type, and application type in several European countries such as the U.K., Germany, France, Italy, Spain, Nordics, BENELUX, and the Rest of Western Europe are included in this chapter.

Chapter 7 – Eastern Europe Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

This chapter introduces the biopharmaceutical contract manufacturing market in the Eastern European region, by providing detailed information about the growth avenues for market players in the region, and growth prospects of the market based on its leading segments. Countries analysed in this region include Russia, Poland, and the Rest of Eastern Europe.

Chapter 8 – APEJ Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

Readers can find important factors that can make a huge impact on the growth of the biopharmaceutical contract manufacturing market in Asia Pacific Excluding Japan (APEJ), based on platform type, product type, therapeutic area type, and application type, during the forecast period. This chapter provides an overview of the regulations, drivers, restraints, and trends in the APEJ biopharmaceutical contract manufacturing market. Countries analysed include China, India, ASEAN, and Australia & New Zealand (ANZ), and the Rest of APEJ.

Chapter 9 – Japan Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

A detailed assessment of the Japanese biopharmaceutical contract manufacturing market has been provided in this chapter. Readers can find thorough information about the growth parameters of the Japanese biopharmaceutical contract manufacturing market during the period 2017-2027.

Chapter 10 – MEA Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

This chapter provides information on how the biopharmaceutical contract manufacturing market - based on platform type, product type, therapeutic area type, and application type - is expected to grow in the major countries or country groups in the MEA region, such as GCC Countries, South Africa, and Rest of MEA, during the period 2017-2027.

Chapter 11 – Forecast Factors

This chapter provides a detailed analysis of the various forecast factors that are estimated to affect the growth of the biopharmaceutical contract manufacturing market in all regions analysed. Factors have been given due weightage as per their impacts on biopharmaceutical contract manufacturing, and a holistic approach has been designed to validate the growth rates across all segments of biopharmaceutical contract manufacturing market.

Chapter 12 – Competition Landscape, Company Share and Company Profiles

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the biopharmaceutical contract manufacturing market, along with detailed information about each company, including company overview, revenue shares, strategic overview, and recent company developments. Some of the biopharmaceutical contract manufacturing market players featured in the report include Lonza Group Ag, Baxter Biopharma solution, Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim Gmbh, Patheon N.V., Rentschler Biotechnologie Gmbh, Catalent Inc., AbbVie Contract Manufacturing, and Ajinomoto Althea Inc.

Chapter 13 - Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027 by Region

This chapter explains how the biopharmaceutical contract manufacturing market will grow across seven geographic regions, such as North America, Latin America, Western Europe, Eastern Europe, Japan, Asia Pacific Excluding Japan (APEJ), and the Middle East & Africa (MEA).

Chapter 14 - Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027 by Platform Type

This chapter explains how the biopharmaceutical contract manufacturing market will grow across all platform types, namely, mammalian and microbial.

Chapter 15- Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027 by Product Type

Based on product type, the biopharmaceutical contract manufacturing market is segmented into monoclonal antibodies, recombinant proteins, vaccines, insulin, interferons, growth factors, and others. In this chapter, readers can find information about the key trends and developments in the biopharmaceutical contract manufacturing market and market attractive analysis based on product type.

Chapter 16 - Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027 by Application

In this chapter, the biopharmaceutical contract manufacturing market is classified by application, into clinical and commercial, highlighting historical trends, current market value, and future projections on the basis of key segments.

Chapter 17 - Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027 by Therapeutic Area

In this chapter, the biopharmaceutical contract manufacturing market has been segmented by therapeutic area into autoimmune diseases, oncology, metabolic diseases, ophthalmology, cardiovascular diseases, infectious diseases, neurology, respiratory disorders, and others. Biopharmaceutical contract manufacturing Market value analysis has been provided for both, the historical and forecast periods.

Chapter 18 – Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the biopharmaceutical contract manufacturing market report.

Chapter 19 – Research Methodology

This chapter helps readers understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the biopharmaceutical contract manufacturing market.

Biopharmaceutical Contract Manufacturing Market Reports - Table of Contents

Biopharmaceutical Contract Manufacturing Market Reports - List of Tables

  1. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country

  2. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

  3. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

  4. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

  5. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

  6. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country

  7. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

  8. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

  9. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

  10. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

  11. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country

  12. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

  13. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

  14. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

  15. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

  16. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country

  17. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

  18. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

  19. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

  20. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

  21. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country

  22. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

  23. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

  24. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

  25. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

  26. Japan Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

  27. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

  28. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

  29. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

  30. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country

  31. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

  32. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

  33. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

  34. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

  35. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Region

  36. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

  37. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

  38. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

  39. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Biopharmaceutical Contract Manufacturing Market Reports - List of Figures

  1. North America Biopharmaceutical Contract Manufacturing Market Value Share By Platform (2017)

  2. North America Biopharmaceutical Contract Manufacturing Market Value Share By Product Type (2017)

  3. North America Biopharmaceutical Contract Manufacturing Market Value Share By Application (2017)

  4. North America Biopharmaceutical Contract Manufacturing Market Value Share By Therapeutic Area (2017)

  5. North America Biopharmaceutical Contract Manufacturing Market Value Share By Country (2017)

  6. North America Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) Analysis, 2012–2016

  7. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 20172027

  8. U.S. Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  9. Canada Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  10. North America Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Mammalian-based Platform, 2012–2016

  11. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Mammalian-based Platform, 2017–2027

  12. North America Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Microbial-based Platform, 2012–2016

  13. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Microbial-based Platform, 2017–2027

  14. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Monoclonal Antibodies, 2012–2027

  15. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Recombinant Proteins, 2012–2027

  16. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Vaccines, 2012–2027

  17. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Insulin, 2012–2027

  18. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Interferons, 2012–2027

  19. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Growth Factors, 2012–2027

  20. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Others, 2012–2027

  21. North America Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Clinical Application, 2012–2016

  22. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Clinical Application, 2017–2027

  23. North America Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Commercial Application, 2012–2016

  24. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Commercial Application, 2017–2027

  25. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Autoimmune Disease, 2012–2027

  26. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Oncology, 2012–2027

  27. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Metabolic Disease, 2012–2027

  28. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Ophthalmology, 2012–2027

  29. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Cardiovascular Disease, 2012–2027

  30. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Infectious Disease, 2012–2027

  31. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Neurology, 2012–2027

  32. North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Respiratory Disorder, 2012–2027

  33. North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Platform, 2017–2027 

  34. North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Product Type, 2017–2027 

  35. North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Application, 2017–2027 

  36. North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Therapeutic Area, 2017–2027 

  37. North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Country, 2017–2027 

  38. Latin America Biopharmaceutical Contract Manufacturing Market Value Share By Platform (2017)

  39. Latin America Biopharmaceutical Contract Manufacturing Market Value Share By Product Type (2017)

  40. Latin America Biopharmaceutical Contract Manufacturing Market Value Share By Application (2017)

  41. Latin America Biopharmaceutical Contract Manufacturing Market Value Share By Therapeutic Area (2017)

  42. Latin America Biopharmaceutical Contract Manufacturing Market Value Share By Country (2017)

  43. Latin America Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) Analysis, 2012–2016

  44. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2027

  45. Brazil Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  46. Mexico Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  47. Rest of Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  48. Latin America Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Mammalian-based Platform, 2012–2016

  49. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Mammalian-based Platform, 2017–2027

  50. Latin America Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Microbial-based Platform, 2012–2016

  51. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Microbial-based Platform, 2017–2027

  52. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Monoclonal Antibodies, 2012–2027

  53. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Recombinant Proteins, 2012–2027

  54. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Vaccines, 2012–2027

  55. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Insulin, 2012–2027

  56. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Interferons, 2012–2027

  57. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Growth Factors, 2012–2027

  58. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Others, 2012–2027

  59. Latin America Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Clinical Application, 2012–2016

  60. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Clinical Application, 2017–2027

  61. Latin America Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Commercial Application, 2012–2016

  62. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Commercial Application, 2017–2027

  63. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Autoimmune Disease, 2012–2027

  64. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Oncology, 2012–2027

  65. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Metabolic Disease, 2012–2027

  66. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Ophthalmology, 2012–2027

  67. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Cardiovascular Disease, 2012–2027

  68. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Infectious Disease, 2012–2027

  69. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Neurology, 2012–2027

  70. Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Respiratory Disorder, 2012–2027

  71. Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Platform, 2017–2027 

  72. Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Product Type, 2017–2027 

  73. Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Application, 2017–2027 

  74. Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Therapeutic Area, 2017–2027 

  75. Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Country, 2017–2027 

  76. Western Europe Biopharmaceutical Contract Manufacturing Market Value Share By Platform (2017)

  77. Western Europe Biopharmaceutical Contract Manufacturing Market Value Share By Product Type (2017)

  78. Western Europe Biopharmaceutical Contract Manufacturing Market Value Share By Application (2017)

  79. Western Europe Biopharmaceutical Contract Manufacturing Market Value Share By Therapeutic Area (2017)

  80. Western Europe Biopharmaceutical Contract Manufacturing Market Value Share By Country (2017)

  81. Western Europe Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) Analysis, 2012–2016

  82. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2027

  83. UK Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  84. Germany Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  85. France Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  86. Italy Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  87. Spain Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  88. Benelux Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  89. Nordic Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  90. Rest of Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  91. Western Europe Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Mammalian-based Platform, 2012–2016

  92. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Mammalian-based Platform, 2017–2027

  93. Western Europe Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Microbial-based Platform, 2012–2016

  94. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Microbial-based Platform, 2017–2027

  95. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Monoclonal Antibodies, 2012–2027

  96. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Recombinant Proteins, 2012–2027

  97. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Vaccines, 2012–2027

  98. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Insulin, 2012–2027

  99. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Interferons, 2012–2027

  100. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Growth Factors, 2012–2027

  101. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Others, 2012–2027

  102. Western Europe Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Clinical Application, 2012–2016

  103. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Clinical Application, 2017–2027

  104. Western Europe Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Commercial Application, 2012–2016

  105. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Commercial Application, 2017–2027

  106. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Autoimmune Disease, 2012–2027

  107. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Oncology, 2012–2027

  108. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Metabolic Disease, 2012–2027

  109. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Ophthalmology, 2012–2027

  110. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Cardiovascular Disease, 2012–2027

  111. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Infectious Disease, 2012–2027

  112. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Neurology, 2012–2027

  113. Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Respiratory Disorder, 2012–2027

  114. Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Platform, 2017–2027 

  115. Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Product Type, 2017–2027 

  116. Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Application, 2017–2027 

  117. Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Therapeutic Area, 2017–2027 

  118. Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Country, 2017–2027 

  119. Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share By Platform (2017)

  120. Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share By Product Type (2017)

  121. Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share By Application (2017)

  122. Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share By Therapeutic Area (2017)

  123. Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share By Country (2017)

  124. Eastern Europe Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) Analysis, 2012–2016

  125. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2027

  126. Russia Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  127. Poland Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  128. Rest of Western Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  129. Eastern Europe Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Mammalian-based Platform, 2012–2016

  130. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Mammalian-based Platform, 2017–2027

  131. Eastern Europe Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Microbial-based Platform, 2012–2016

  132. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Microbial-based Platform, 2017–2027

  133. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Monoclonal Antibodies, 2012–2027

  134. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Recombinant Proteins, 2012–2027

  135. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Vaccines, 2012–2027

  136. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Insulin, 2012–2027

  137. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Interferons, 2012–2027

  138. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Growth Factors, 2012–2027

  139. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Others, 2012–2027

  140. Eastern Europe Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Clinical Application, 2012–2016

  141. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Clinical Application, 2017–2027

  142. Eastern Europe Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Commercial Application, 2012–2016

  143. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Commercial Application, 2017–2027

  144. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Autoimmune Disease, 2012–2027

  145. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Oncology, 2012–2027

  146. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Metabolic Disease, 2012–2027

  147. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Ophthalmology, 2012–2027

  148. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Cardiovascular Disease, 2012–2027

  149. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Infectious Disease, 2012–2027

  150. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Neurology, 2012–2027

  151. Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Respiratory Disorder, 2012–2027

  152. Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Platform, 2017–2027 

  153. Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Product Type, 2017–2027 

  154. Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Application, 2017–2027 

  155. Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Therapeutic Area, 2017–2027 

  156. Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Country, 2017–2027 

  157. APEJ Biopharmaceutical Contract Manufacturing Market Value Share By Platform (2017)

  158. APEJ Biopharmaceutical Contract Manufacturing Market Value Share By Product Type (2017)

  159. APEJ Biopharmaceutical Contract Manufacturing Market Value Share By Application (2017)

  160. APEJ Biopharmaceutical Contract Manufacturing Market Value Share By Therapeutic Area (2017)

  161. APEJ Biopharmaceutical Contract Manufacturing Market Value Share By Country (2017)

  162. APEJ Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) Analysis, 2012–2016

  163. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2027

  164. China Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  165. India Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  166. Australia & New Zealand Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  167. ASEAN Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By, 2012–2027

  168. South Korea Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  169. Rest of APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%)By  Rest oJ, 2012–2027

  170. APEJ Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Mammalian-based Platform, 2012–2016

  171. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Mammalian-based Platform, 2017–2027

  172. APEJ Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Microbial-based Platform, 2012–2016

  173. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Microbial-based Platform, 2017–2027

  174. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Monoclonal Antibodies, 2012–2027

  175. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Recombinant Proteins, 2012–2027

  176. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Vaccines, 2012–2027

  177. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Insulin, 2012–2027

  178. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Interferons, 2012–2027

  179. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Growth Factors, 2012–2027

  180. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Others, 2012–2027

  181. APEJ Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Clinical Application, 2012–2016

  182. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Clinical Application, 2017–2027

  183. APEJ Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Commercial Application, 2012–2016

  184. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Commercial Application, 2017–2027

  185. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Autoimmune Disease, 2012–2027

  186. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Oncology, 2012–2027

  187. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Metabolic Disease, 2012–2027

  188. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Ophthalmology, 2012–2027

  189. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Cardiovascular Disease, 2012–2027

  190. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Infectious Disease, 2012–2027

  191. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Neurology, 2012–2027

  192. APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Respiratory Disorder, 2012–2027

  193. APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Platform, 2017–2027 

  194. APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Product Type, 2017–2027 

  195. APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Application, 2017–2027 

  196. APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Therapeutic Area, 2017–2027 

  197. APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Country, 2017–2027 

  198. Japan  Biopharmaceutical Contract Manufacturing Market Value Share By Platform (2017)

  199. Japan  Biopharmaceutical Contract Manufacturing Market Value Share By Product Type (2017)

  200. Japan  Biopharmaceutical Contract Manufacturing Market Value Share By Application (2017)

  201. Japan  Biopharmaceutical Contract Manufacturing Market Value Share By Therapeutic Area (2017)

  202. Japan  Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) Analysis, 2012–2016

  203. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2027

  204. Japan  Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Mammalian-based Platform, 2012–2016

  205. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Mammalian-based Platform, 2017–2027

  206. Japan  Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Microbial-based Platform, 2012–2016

  207. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Microbial-based Platform, 2017–2027

  208. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Monoclonal Antibodies, 2012–2027

  209. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Recombinant Proteins, 2012–2027

  210. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Vaccines, 2012–2027

  211. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Insulin, 2012–2027

  212. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Interferons, 2012–2027

  213. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Growth Factors, 2012–2027

  214. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Others, 2012–2027

  215. Japan  Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Clinical Application, 2012–2016

  216. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Clinical Application, 2017–2027

  217. Japan  Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Commercial Application, 2012–2016

  218. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Commercial Application, 2017–2027

  219. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Autoimmune Disease, 2012–2027

  220. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Oncology, 2012–2027

  221. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Metabolic Disease, 2012–2027

  222. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Ophthalmology, 2012–2027

  223. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Cardiovascular Disease, 2012–2027

  224. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Infectious Disease, 2012–2027

  225. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Neurology, 2012–2027

  226. Japan  Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Respiratory Disorder, 2012–2027

  227. Japan  Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Platform, 2017–2027 

  228. Japan  Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Product Type, 2017–2027 

  229. Japan  Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Application, 2017–2027 

  230. Japan  Biopharmaceutical Contract Manufacturing Market     Attractiveness Analysis By Therapeutic Area, 2017–2027 

  231. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share By Platform (2017)

  232. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share By Product Type (2017)

  233. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share By Application (2017)

  234. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share By Therapeutic Area (2017)

  235. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share By Country (2017)

  236. Middle East & Africa Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) Analysis, 2012–2016

  237. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2027

  238. GCC Countries Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  239. Turkey Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  240. North Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  241. South Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  242. Rest of Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%), 2012–2027

  243. Middle East & Africa Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Mammalian-based Platform, 2012–2016

  244. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Mammalian-based Platform, 2017–2027

  245. Middle East & Africa Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Microbial-based Platform, 2012–2016

  246. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Microbial-based Platform, 2017–2027

  247. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Monoclonal Antibodies, 2012–2027

  248. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Recombinant Proteins, 2012–2027

  249. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Vaccines, 2012–2027

  250. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Insulin, 2012–2027

  251. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Interferons, 2012–2027

  252. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Growth Factors, 2012–2027

  253. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Others, 2012–2027

  254. Middle East & Africa Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Clinical Application, 2012–2016

  255. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Clinical Application, 2017–2027

  256. Middle East & Africa Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Commercial Application, 2012–2016

  257. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Commercial Application, 2017–2027

  258. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Autoimmune Disease, 2012–2027

  259. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Oncology, 2012–2027

  260. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Metabolic Disease, 2012–2027

  261. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Ophthalmology, 2012–2027

  262. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Cardiovascular Disease, 2012–2027

  263. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Infectious Disease, 2012–2027

  264. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Neurology, 2012–2027

  265. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Respiratory Disorder, 2012–2027

  266. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Platform, 2017–2027 

  267. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Product Type, 2017–2027 

  268. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Application, 2017–2027 

  269. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Therapeutic Area, 2017–2027 

  270. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Country, 2017–2027 

  271. Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Growth (%) 2017–2027, By Region

  272. Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Region, 2017–2027 

  273. Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Growth (%) 2017–2027, By Platform

  274. Global Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Mammalian-based Platform, 2012–2016

  275. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Mammalian-based Platform, 2017–2027

  276. Global Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Microbial-based Platform, 2012–2016

  277. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Microbial-based Platform, 2017–2027

  278. Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Platform, 2017–2027 

  279. Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Growth (%) 2017–2027, By Product Type

  280. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Monoclonal Antibodies, 2012–2027

  281. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Recombinant Proteins, 2012–2027

  282. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Vaccines, 2012–2027

  283. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Insulin, 2012–2027

  284. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Interferons, 2012–2027

  285. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Growth Factors, 2012–2027

  286. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Others, 2012–2027

  287. Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Product Type, 2017–2027 

  288. Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Growth (%) 2017–2027, By Application

  289. Global Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Clinical Application, 2012–2016

  290. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Clinical Application, 2017–2027

  291. Global Biopharmaceutical Contract Manufacturing Historical Market Size (US$ Mn) By Commercial Application, 2012–2016

  292. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Commercial Application, 2017–2027

  293. Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Application, 2017–2027 

  294. Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Growth (%) 2017–2027, By Therapeutic Area

  295. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Autoimmune Disease, 2012–2027

  296. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Oncology, 2012–2027

  297. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Metabolic Disease, 2012–2027

  298. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Ophthalmology, 2012–2027

  299. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Cardiovascular Disease, 2012–2027

  300. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Infectious Disease, 2012–2027

  301. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Neurology, 2012–2027

  302. Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) & Y-o-Y Growth (%) By Respiratory Disorder, 2012–2027

  303. Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis By Therapeutic Area, 2017–2027 

Get in touch

Harish Tiwari

Global Head - Business Development

+44 (0) 20 3287 4268

Pranay Mhaisekar

Business Development

+ 44 (0) 20 7692 8790
* indicates mandatory fields.

Latest Insights

Our Clients

Press Releases:

Recommendations

CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Learn More
Request Sample Ask An Analyst Request Special Price Request Methodology